

# CURRICULUM VITAE

## 1. Dati personali

Cognome Nome	<b>GRELLI SANDRO</b>
Data e Luogo di Nascita	Born in Rome on 12 December 1959
Amministrazione	University of Roma "Tor Vergata" – Dipt. Experimental Medicine
Tel Ufficio e Fax	+390620900678; +390620900413
e-mail	grelli@med.uniroma2.it
Cittadinanza	Italian

## 2. Istruzione (documentata quella universitaria)

<i>Anni</i>	<i>Profilo di Istruzione compiuta, Istituzione, Luogo</i>
-------------	---

Master Degree in Medicine and Surgery (110/110 cum laude) at the University of Rome La Sapienza in 25 October 1985.

## 3. Formazione Post-Laurea (documentata)

<i>Anno/i</i>	<i>Profilo di Formazione compiuta, Durata, Istituzione, Luogo</i>
---------------	---

Post graduate Master in "Strategic Acquisition of Technologies for Laboratory Medicine" - IV edition, organized by the LUISS Business School - Division of LUISS Guido Carli. (2016)

Post Graduate Specialization Course in "Oncology" (70/70 cum laude) at the University of Rome "Tor Vergata" (1989)

## 4. Titoli (scientifici/accademici/altri) e qualifiche in possesso (documentati)

<i>Titolo</i>	<i>Anno</i>	<i>Istituzione di emanazione, Luogo</i>
---------------	-------------	---

Scientific national habilitation (ASN) as Full Professor of Microbiology and Clinic Microbiology (MED 07), Italian Ministry of University and Research (MIUR). (From 2021)

Director of Post Graduate Specialization Course in "Microbiology and Virology" at the University of Rome "Tor Vergata"(From 2018)

Director of Degree course in "Diagnostic Techniques of Biomedical Laboratory" at the University of Rome "Tor Vergata" (from 2018)

Associate Professor in Microbiology and Clinical Microbiology MED/07 at the University of Rome "Tor Vergata" (from 2010)

Researcher in Microbiology and Clinical Microbiology MED/07 (1988) at the University of Rome "Tor Vergata" (from 1998)

## 5. Esperienze lavorative

<i>Anno/i</i>	<i>Funzione, Tipologia del lavoro, Istituzione-Struttura, Luogo</i>
---------------	---

**ASSISTENTIAL POSITION:** Since 2018, he coordinates the **Virology Unit** and currently participates in the **Task Force COVID-19** of Tor Vergata Hospital in Rome. The laboratory has been identified by the Lazio Region among those authorized to carry out molecular diagnosis on respiratory clinical samples according to specific Real Time PCR protocols for SARS-CoV-2. The Laboratory belongs to the CoroNET network of the Lazio Region, which has the National Institute for Infectious Diseases - IRCCS "Lazzaro Spallanzani" as coordination of all laboratories.

**From 1 March 2001** to September 2018, he has the **head of the Cellular Immunology and Bacteriological Serology Service** at the Tor Vergata Hospital.

**1994-1998** CNR contract Researcher, at the Institute of Experimental Medicine of the CNR in Rome, for a research program concerning "Programmed cell death, with particular reference to the death of human lymphocytes, connected with human retrovirus infection ", to be carried out in collaboration with the chair of Microbiology of the University of Rome" Tor Vergata "directed by Prof. Enrico Garaci, from 16.02.1994 to 01.11.1998.

**C.V.. Prof. Sandro Grelli**

**1994-1996** Visitor of foreign institutions: he was involved in a scientific-educational activity for a cooperation project entitled "Medical Research Institute of Alexandria University (Egypt) reinforcement", funded by the ministry of foreign affairs in the period from 1994 to 1996.

The activities were carried out at the Department of Experimental Medicine and Biochemical Sciences of the University of Rome "Tor Vergata" in Italy and at the "Medical Research Institute" of Alessandria in Egypt..

**1988-1993** CNR contract Researcher at the Institute of Experimental Medicine of the CNR in Rome, for a research program on "Cellular and Molecular Immunology", to be carried out in collaboration with the chair of Microbiology of the University of Rome "Tor Vergata"

**1989** CNR grant for the topic: "Immunomodulating drugs in infectious diseases" at the Institute of Experimental Medicine of the CNR in Rome, in collaboration with Microbiology chair of the University of Rome "Tor Vergata" Directed by Prof. Enrico Garaci.

Military service as a Medical Officer in the Air Force from 10.09.1986 to 09.12.1987.

## 6. Esperienze didattiche

Anno/i	Disciplina insegnata, Corso di..., Tipologia (lez./eserc.), Istituzione, Luogo
--------	--

2002 to date: he was a member of the teaching staff of several PhD programs at the University of Rome "Tor Vergata":

Laboratory Medicine;

Medical Biotechnology and Molecular Medicine;

Medical Microbiology,

Immunology and Infectious Diseases;

Medical Microbiology, Immunology, Infectious Diseases, Organ Transplants and Related Pathologies; Microbiology, Immunology, Infectious Diseases, Transplants (MIMIT)

2002 to date: member of the Board of several Specialization course such as Clinical Pathology and Clinical Biochemistry, Microbiology and Virology, Oncology, Ophthalmology, Urology, Dermatology and Venereology and Oral Cavity Surgery, at the University of Rome Tor Vergata.

1999 to date: charged for teaching Microbiology and Clinical Microbiology disciplines at the Faculty of Medicine of the University of Rome "Tor Vergata", in the following degree courses: Medicine, Dentistry, Dental Hygienist, Nursing, Obstetrics, Biomedical Laboratory Technician, Orthoptists, Workplace and Environment Prevention Technician. He supervised the theoretical-practical and training course as well as the preparation of the degree Specialization thesis of several students.

## 7. Esperienze didattiche Università straniere

Anno/i	Funzione/ Tipologia dell'impegno, Istituzione-Struttura, Luogo
--------	--

2017 to date: charged for teaching the Microbiology and Clinical Microbiology Course for Nursing at the Catholic University of Tirana "Our Lady of Good Council"

2005 to date: charged for teaching the Microbiology Course for Dentistry at the Catholic University of Tirana "Our Lady of Good Council"

## 8. Altre funzioni svolte

In 2018 he is one of the founding members of the **Tor Vergata Oncoscience Research (TOR)** Center of Excellence, founded at our University on 7/19/2018 with Rector's Decree 1407/2018 (protocol 0024695/2018). The TOR is a consortium that promotes cancer research at an international level to create a pole that strengthens the leadership and visibility of Rome on the international scene. The TOR facilitates interaction between local and international science, contributing to the development of the local clinical and academic community in oncology. TOR aims to be a central position in the international network of all European and international cancer research institutes interested in scientific collaboration.

For the Consortium, the scientific activity of Prof. Grelli focuses on the microorganism / host interaction for the understanding of viral infections and the mechanism involved in the etiopathogenesis of associated chronic diseases.

Anno/i	Capacità competenze tecniche
--------	------------------------------

## 9. Pubblicazioni scientifiche dall'anno 1985

Autori, Anno, Titolo del lavoro, referenze organo editore (nome, nr , pagine, luogo di edizione)
--

SCIENTIFIC PUBLICATIONS: 98 article publications in journals (h-index 23) and over 200 international and national communication abstracts.

### SCIENTIFIC PUBLICATIONS SINCE 2000

1. Alkhatib M, Bellocchi MC, Marchegiani G, **Grelli S**, Micheli V, Stella D, Zerillo B, Carioti L, Svicher V, Rogliani P, Ceccherini-Silberstein F. First Case of a COVID-19 Patient Infected by Delta AY.4 with a Rare Deletion Leading to a N Gene Target Failure by a Specific Real Time PCR Assay: Novel Omicron VOC Might Be Doing Similar Scenario? **2022 Microorganisms**. Jan 25;10(2):268. doi:10.3390/microorganisms10020268. PMID: 35208724. **IF:4.167**
2. Coppeta L, Ferrari C, Somma G, Mazza A, D'ancona U, Marcuccilli F, **Grelli S**, Aurilio MT, Pietroiusti A, Magrini A, Rizza S. Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine. **2022 Vaccines**. Jan 18;10(2):141. doi:10.3390/vaccines10020141. PMID: 35214600. Citato 1 volta. **IF:4.760**
3. Iannetta M, Landi D, Cola G, Campogiani L, Malagnino V, Teti E, Coppola L, Di Lorenzo A, Fraboni D, Buccisano F, **Grelli S**, Mozzani M, Zingaropoli MA, Ciardi MR, Nisini R, Bernardini S, Andreoni M, Marfia GA, Sarmati L. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications. **2022 Front Immunol**. Jan 17;12:796482. doi:10.3389/fimmu.2021.796482. PMID: 35111162. **IF:7.561**
4. Minutolo A, Petrone V, Fanelli M, Iannetta M, Giudice M, Belkacem IA, Zordan M, Vitale P, Rasi G, Sinibaldi-Vallebona P, Sarmati L, Andreoni M, Malergue F, Balestrieri E, **Grelli S**, Matteucci C. High CD169 monocyte/lymphocyte ratio reflects immunophenotype disruption and oxygen need in COVID-19 patients. **2021 Pathogens**. Dec 18;10(12):1639. doi:10.3390/pathogens10121639. PMID: 34959594. **IF:3.405**
5. Piermatteo L, Alkhatib M., D'anna S, Malagnino V, Bertoli A, Andreassi E, Basile E, Iuvara A, De Cristofaro M, Cappiello G, Cerva C, Minichini C, Pisaturo M, Starace M, Coppola N, Fontana C, **Grelli S**, Ceccherini-Silberstein F, Andreoni M, Gill US, Kennedy PTF, Sarmati L, Salpini R, Svicher V. Hbeag levels vary across the different stages of hbv infection according to the extent of immunological pressure and are associated with therapeutic outcome in the setting of immunosuppression-driven hbv reactivation. **2021 Biomedicines**. Sep 29;9(10):1352. doi:10.3390/biomedicines9101352. PMID: 34680469. **IF:6.081**
6. Cosio T, Gaziano R, Zuccari G, Costanza G, Grelli S, Di Francesco P, Bianchi L, Campione E. Retinoids in fungal infections: From bench to bedside. **2021 Pharmaceuticals**. Sep 24;14(10):962. doi:10.3390/ph14100962. PMID: 34681186. Citato 2 volte. **IF:5.68**
7. Iannetta M, Landi D, Cola G, Malagnino V, Teti E, Fraboni D, Buccisano F, **Grelli S**, Coppola L, Campogiani L, Andreoni M, Marfia GA, Sarmati L. T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers. **2021 Mult Scler Relat Disord**. Oct 55:103157. doi:10.1016/j.msard.2021.103157. PMID: 34418737. Citato 5 volte. **IF:5.412**
8. Aiello F, Ciotti M, Afflitto GG, Rapanotti MC, Caggiano B, Treglia M, **Grelli S**, Bernardini S, Mauriello S, Nucci C, Marsella LT, Mancino R. Post-mortem rt-pcr assay for sars-cov-2 rna in covid-19 patients' corneal epithelium, conjunctival and nasopharyngeal swabs. **2021 J Clin Med**. Sep 20;10(18):4256. doi:10.3390/jcm10184256. PMID: 34575369. Citato 2 volte. **IF:5.583**
9. Rizza S, Coppeta L, Grelli S, Ferrazza G, Chiocchi M, Vanni G, Bonomo OC, Bellia A, Andreoni M, Magrini A, Federici, M. High body mass index and night shift work are associated with COVID-19 in health

- care workers. **2021 J Endocrinol Invest.** May; 44(5):1097-1101. doi:10.1007/s40618-020-01397-0. PMID: 32852704. Citato 14 volte. **IF:3.166**
10. Balestrieri E, Minutolo A, Petrone V, Fanelli M, Iannetta M, Malagnino V, Zordan M, Vitale P, Charvet B, Horvat B, Bernardini S, Garaci E, di Francesco P, Sinibaldi Vallebona P, Sarmati L, **Grelli S**, Andreoni M, Perron H, Matteucci C. Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients. **2021 EBioMedicine.** Apr 66:103341. doi:10.1016/j.ebiom.2021.103341. PMID: 33867312. Citato 9 volte. **IF:8.143**
  11. Pieri M, Nuccetelli M, Nicolai E, Sarubbi S, **Grelli S**, Bernardini S. Clinical validation of a second generation anti-SARS-CoV-2 IgG and IgM automated chemiluminescent immunoassay. **2021 J Med Virol.** Apr;93(4):2523-2528. doi:10.1002/jmv.26809. PMID: 33463719. Citato 3 volte. **IF:2.327**
  12. Novelli G, Liu J, Biancolella M, Alonzi T, Novelli A, Patten JJ, Cocciadiferro D, Agolini E, Colona VL, Rizzacasa B, Giannini R, Bigio B, Goletti D, Capobianchi MR, **Grelli S**, Mann J, McKee TD, Cheng K, Amanat F, Krammer F, Guarracino A, Pepe G, Tomino C, Tandjaoui-Lambiotte Y, Uzunhan Y, Tubiana S, Ghosn J, Notarangelo LD, Su HC, Abel L, Cobat A, Elhanan G, Grzymalski JJ, Latini A, Sidhu SS, Jain S, Davey RA, Casanova J-L, Wei W, Pandolfi PP. COVID Human Genetic Effort, French COVID Cohort Study Group, CoV-Contact Cohort Inhibition of HECT E3 ligases as potential therapy for COVID-19. **2021 Cell Death Dis.** Feb 11;11:620038. doi:10.1038/s41419-021-03513-1. PMID: 33643043. Citato 9 volte. **IF:8.469**
  13. Minutolo A, Potestà M, Roglia V, Cirilli M, Iacovelli F, Cerva C., Fokam J, Desideri A, Andreoni M, **Grelli S**, Colizzi V, Muleo R, Montesano C. Plant microRNAs from *Moringa oleifera* Regulate Immune Response and HIV Infection. **2021 Front Pharmacol.** Feb 11;11:620038. doi:10.3389/fphar.2020.620038. PMID: 33643043. Citato 2 volte. **IF:4.400**
  14. Matteucci C, Minutolo A, Balestrieri E, Petrone V, Fanelli M, Malagnino V, Iannetta M, Giovinazzo A, Barreca F, Di Cesare S, De Marco P, Miele MT, Toschi N, Mastino A, Sinibaldi Vallebona P, Bernardini S, Rogliani P, Sarmati L, Andreoni M, **Grelli S**, Garaci E. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells from Coronavirus Disease 2019 Patients. **2020 Open Forum Infect Dis.** Dec 5;8(1):ofaa588. doi:10.1093/ofid/ofaa588. PMID: 33506065. Citato 7 volte. **IF:3.835**
  15. Macchi B, Frezza C, Marino-Merlo F, Minutolo A, Stefanizzi V, Balestrieri E, Cerva C, Sarmati L, Andreoni M, **Grelli S**, Mastino A. Appraisal of a simple and effective RT-qPCR assay for evaluating the reverse transcriptase activity in blood samples from HIV-1 patients. **2020 Pathogens.** Dec 13;9(12):1047. doi:10.3390/pathogens9121047. PMID: 33322208. **IF:3.405**
  16. Potestà M, Roglia V, Fanelli M, Pietrobono E, Gismondi A, Vumbaca S, Nguedia Tsangueu RG, Canini A, Colizzi V, **Grelli S**, Minutolo A, Montesano C. Effect of microvesicles from *Moringa oleifera* containing miRNA on proliferation and apoptosis in tumor cell lines. **2020 Cell Death Discov.** Jun 4;6:43. doi:10.1038/s41420-020-0271-6. PMID: 32550010. Citato 10 volte. **IF:4.53**
  17. Campione E, Lanna C, Diluvio L, Cannizzaro MV, **Grelli S**, Galluzzo M, Talamonti M, Annicchiarico-Petruzzelli M, Mancini M, Melino G, Candi E, Schiavone G, Wang Y, Shi Y, Bianchi L. Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. **2020 Cell Cycle.** Feb 19(3):257-267. doi:10.1080/15384101.2019.1707455. PMID: 31905036. **IF:4.534**
  18. Pellicciaro M, Granai AV, Marchese G, Materazzo M, Cotesta M, Santori F, Giacobbi E, Servadei F, **Grelli S**, Perretta T, Meucci R, Pistolese C A, Vanni G. Breast cancer patients with hormone neoadjuvant bridging therapy due to asymptomatic Corona virus infection. Case report, clinical and histopathologic findings. **2020 Int J Surg Case Rep.** Oct 76:377-380, doi:10.1016/j.ijscr.2020.10.020. PMID: 33052300. **IF:0.69**
  19. Matteucci C, Marino-Merlo F, Minutolo A, Balestrieri E, Valletta E, Macchi B, Mastino A, **Grelli S**. [Inhibition of IκBα phosphorylation potentiates regulated cell death induced by azidothymidine in HTLV-1 infected cells.](#) **2020 Cell Death Discov.** Feb 18;6:9. doi:10.1038/s41420-020-0243. PMID: 32123585. **IF:4.53**
  20. Marino-Merlo F, Balestrieri E, Matteucci C, Mastino A, **Grelli S\***, Macchi B\*. [Antiretroviral Therapy in HTLV-1 Infection: An Updated Overview.](#) **2020 Pathogens.** May 1;9(5):342. doi:10.3390/pathogens9050342. PMID: 32369988. Citato 9 volte. **IF:3.405**

21. Nuccetelli M, Pieri M, **Grelli S**, Ciotti M, Miano R, Andreoni M, Bernardini S. [SARS-CoV-2 infection serology: a useful tool to overcome lockdown?](#) **2020 Cell Death Discov.** May 26;6:38. doi:10.1038/s41420-020-0275-2. PMID: 32501411. Citato 45 volte. **IF:4.53**
22. Rizza S, Coppeta L, **Grelli S**, Ferrazza G, Chiochi M, Vanni G, Bonomo OC, Bellia A, Andreoni M, Magrini A, Federici M. Rizza S. [High body mass index and night shift work are associated with COVID-19 in health care workers.](#) **2020 J Endocrinol Invest.** Aug 27;1-5. doi:10.1007/s40618-020-01397-0. PMID: 32852704. Citato 14 volte. **IF:3.166**
23. Novelli A, Biancolella M, Borgiani P, Cocciadiferro D, Colona VL, D'Apice MR, Rogliani P, Zaffina S, Leonardis F, Campana A, Raponi M, Andreoni M, **Grelli S\***, Novelli G.\* [Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients.](#) **2020 Hum Genomics.** Sep 11;14(1):29. doi:10.1186/s40246-020-00279-z. PMID: 32917283. Citato 9 volte. **IF:2.54**
24. Amati F, Vancheri C, Latini A, Colona VL, **Grelli S**, D'Apice MR, Balestrieri E, Passarelli C, Minutolo A, Loddo S, Di Lorenzo A, Rogliani P, Andreoni M, Novelli G. Expression profiles of the SARS-CoV-2 host invasion genes in nasopharyngeal and oropharyngeal swabs of COVID-19 patients. **2020 Heliyon** Oct;6(10):e05143. doi:10.1016/j.heliyon.2020.e05143. Epub 2020 Oct 1. PMID: 33024851. Citato 7 volte. **IF:2.85**
25. Coppeta L, Pietroiusti A, Lieto P, Ferraro M, **Grelli S**, Stillo M, Magrini A. Measles immunity in an Italian teaching hospital. **2019 Occup Med.** Apr 13;69(2):143-145. doi:10.1093/occmed/kqy132. PMID: 30295885. Citato 1 volta. **IF:1.22**
26. Marino-Merlo F, Papaiani E, Frezza C, Pedatella S, De Nisco M, Macchi B, **Grelli S\***, Mastino A.\* [NF-κB-Dependent Production of ROS and Restriction of HSV-1 Infection in U937 Monocytic Cells.](#) **2019 Viruses.** May 10;11(5):428. doi:10.3390/v11050428. PMID: 31083280. Citato da 7. **IF:3.8**
27. Balestrieri E, Cipriani C, Matteucci C, Benvenuto A, Coniglio A, Argaw-Denboba A, Toschi N, Bucci I, Miele MT, **Grelli S**, Curatolo P, Sinibaldi-Vallebona P. Balestrieri E. [Children With Autism Spectrum Disorder and Their Mothers Share Abnormal Expression of Selected Endogenous Retroviruses Families and Cytokines.](#) **2019 Front. Immunol.** Sep 26;10:2244. doi:10.3389/fimmu.2019.02244. MID: 31616420. Citato da 18. **IF:5.085**
28. Pentimalli F, **Grelli S**, Di Daniele N, Melino G, Amelio I. [Cell death pathologies: targeting death pathways and the immune system for cancer therapy.](#) **2019 Genes Immun.** Sep;20(7):539-554. doi:10.1038/s41435-018-0052. PMID: 30563970. Citato da 31. **IF:2.230**
29. Bordoni V, Brando B, Piselli P, Forini O, Perna FE, Atripaldi U, Carputo S, Garziano F, Trento E, D'Agosto G, Latini A, Colafigli M, Cristaudo A, Sacchi A, Andreoni M, De Carli G, Orchi N, **Grelli S**, Gatti A, Cerva C, Minutolo A, Potestà M, Di Martino ML, Ortu F, Selva P, Del Pup L, Guarnori I, Lorenzini P, Capuano G, Antinori A, Agrati C. [Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study.](#) **2019 PLoS One.** Dec 23;14(12):e0225415. doi:10.1371/journal.pone.0225415. PMID: 31869342. Citato da 6. **IF:2.776**
30. Giovinazzo A, Balestrieri E, Petrone V, Argaw-Denboba A, Cipriani C, Miele MT, **Grelli S**, Sinibaldi-Vallebona P, Matteucci C. [The Concomitant Expression of Human Endogenous Retroviruses and Embryonic Genes in Cancer Cells under Microenvironmental Changes is a Potential Target for Antiretroviral Drugs.](#) **2019 Cancer Microenviron.** 2019. Dec;12(2-3):105-118. doi:10.1007/s12307-019-00231-3. PMID: 31691184. Citato da 4. **IF:2.6**
31. Balestrieri E, Matteucci C, Cipriani C, **Grelli\* S**, Ricceri L, Calamandrei G, Vallebona PS\*. [Endogenous Retroviruses Activity as a Molecular Signature of Neurodevelopmental Disorders.](#) **2019 Int J Mol Sci.** Nov 30;20(23):6050. doi:10.3390/ijms20236050. PMID: 31801288. Citato da 7. **IF:4.566**
32. Salpini R, Battisti A, Piermatteo L, Carioti L, Anastasiou OE, Gill US, Di Carlo D, Colagrossi L, Duca L, Bertoli A, La Rosa KY, Fabeni L, Iuvara A, Malagnino V, Cerva C, Lichtner M, Mastroianni CM, De Sanctis GM, Paoloni M, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Vecchiet J, Sarmati L, Andreoni M, Angelico M, **Grelli S**, T Kennedy P, Verheyen J, Aquaro S, Silberstein FC, Perno CF, Svicher V. [Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative](#)

- [chronic HBV genotype-D infection.](#) **2020 Emerg Microbes Infect.** Dec;9(1):928-939. doi:10.1080/22221751.2020.1757998. PMID: 32312174. Citato da 2. **IF:2.21**
33. Campogiani L, Compagno M, Coppola L, Malagnino V, Maffongelli G, Saraca LM, Francisci D, Baldelli F, Fontana C, **Grelli S**, Andreoni M, Sotgiu G, Sadleri L, Sarmati L. [Tuberculosis-Related Hospitalizations in a Low-Incidence Country: A Retrospective Analysis in Two Italian Infectious Diseases Wards.](#) **2019 Int J Environ Res Public Health.** Dec 23;17(1):124. doi:10.3390/ijerph17010124. PMID: 31878009. Citato da 3. **IF:4.519**
  34. Agostini M, Niklison-Chirou MV, Annicchiarico-Petruzzelli MM, **Grelli S**, Di Daniele N, Pestlikis I, Knight RA, Melino G, Rufini A. p73 Regulates Primary Cortical Neuron Metabolism: a Global Metabolic Profile. **2018. Mol Neurobiol.** May 6. doi:10.1007/s12035-017-0517-3. PMID: 28478509. Citato da 9. **IF:4.586**
  35. Marino-Merlo F, Mastino A, **Grelli S**, Hermine O, Bazarbachi A, Macchi B. [Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma.](#) **2018 Front Microbiol.** May 9:925. doi:10.3389/fmicb.2018.00925. PMID: 29867836. Citato da 8. **IF:4.076**
  36. Matteucci C, Argaw-Denboba A, Balestrieri E, Giovinazzo A, Miele M, D'Agostini C, Pica F, **Grelli S**, Paci M, Mastino A, Sinibaldi-Vallebona P, Garaci E, Tomino C. Deciphering cellular biological processes to clinical application: a new perspective for T $\alpha$ 1 treatment targeting multiple diseases. **2018 Expert Opin Biol Ther.** Jul;18(sup1):23-31. doi:10.1080/14712598.2018.1474198. PMID: 30063863. Citato da 7. **IF: 3.224**
  37. Cipriani C, Ricceri L, Matteucci C, De Felice A, Tartaglione AM, Argaw-Denboba A, Pica F, **Grelli S**, Calamandrei G, Sinibaldi-Vallebona P, Balestrieri E. High expression of Endogenous Retroviruses from intrauterine life to adulthood in two mouse models of Autism Spectrum Disorders. **2018 Sci Rep.** Jan 12;8(1):629. doi:10.1038/s41598-017-19035-w. PMID: 29330412. Citato da 19. **IF:4.12**
  38. Cipriani C, Pitzianti C, L, Matteucci C, D'Agati E, Miele MT, Argaw-Denboba A, Rapaccini V, **Grelli S**, Curatolo P, Sinibaldi-Vallebona P, Pasini A, Balestrieri E. The decrease in Human Endogenous Retroviruses H-activity runs in parallel with improvement in ADHD symptoms in patients undergoing mettylphenidate therapy. **2018 Int J Mol Sci.** Dec 23;19 (11):629. pii:E3268 doi:10.3390/ijms19113386. PMID: 30360480. Citato da 9. **IF: 3.687**
  39. Marino-Merlo F, Macchi B, Armenia D, Bellocchi MC, Ceccherini-Silberstein F, Mastino A, **Grelli S**. Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors. **2018 Appl Microbiol Biotechnol.** Dec;102(23):9925-9936. doi:10.1007/s00253-018-9390-x. Epub 2018 Sep 29. PMID: 30269214. Citato da 3. **IF:3.340**
  40. Matteucci C, **Grelli S**, Balestrieri E, Minutolo A, Argaw-Denboba A, Macchi B, Sinibaldi-Vallebona P, Perno CF, Mastino A, Garaci E. Thymosin alpha 1 and HIV-1: recent advances and future perspectives. **2017 Future Microbiol.** Feb;12:141-155. doi:10.2217/fmb-2016-0125. PMID: 28106477. Citato da 32. **IF:2.907**
  41. Macchi B, Balestrieri E, Frezza C, **Grelli S**, Valletta E, Marçais A, Marino-Merlo F, Turpin J, Bangham CR, Hermine O, Mastino A, Bazarbachi A. [Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon- \$\alpha\$ .](#) **2017 Blood Adv.** May 5;1(12):748-752. doi:10.1182/bloodadvances.2016001370. PMID: 29296718. Citato da 17. **IF:6.799**
  42. Frezza C, **Grelli S.**, Federico M, Marino-Merlo F, Mastino A, Macchi B. Testing anti-HIV activity of antiretroviral agents in vitro using flow cytometry analysis of CEM-GFP cells infected with transfection-derived HIV-1 NL4-3. **2016 J Med Virol.** Jun;88(6):979-86. doi:10.1002/jmv.24418. PMID: 26519867. Citato da 6. **IF:2.021**
  43. Marino-Merlo F, Papianni E, Medici MA, Macchi B, **Grelli S**, Mosca C, Borner C, Mastino A. HSV-1-induced activation of NF- $\kappa$ B protects U937 monocytic cells against both virus replication and apoptosis. **2016 Cell Death Dis.** Sep 1;7(9):e2354. doi:10.1038/cddis.2016.250. PMID: 27584793. Citato da 14. **IF:6.234**
  44. Matteucci C, Minutolo A, Marino-Merlo F, **Grelli S**, Frezza C, Mastino A, Macchi B. Characterization of the enhanced apoptotic response to azidothymidine by pharmacological inhibition of NF-kB. **2015 Life Sci.** Mar 2. pii: S0024-3205(15)00110-1. doi:10.1016/j.lfs.2015.01.038. PMID: 25744407. Citato da 18. **IF:2.296**

45. Matteucci C, Minutolo A, Pollicita M, Balestrieri E, **Grelli S**, D'Etto G, Vullo V, Bucci I, Luchini A, Aquaro S, Sinibaldi-Vallebona P, Macchi B, Perno CF, Mastino A, Garaci E. Thymosin  $\alpha$  1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro. **2015 Expert Opin Biol Ther.** 15 Suppl 1:S83-100. doi:10.1517/14712598.2015.1021677. Epub 2015 Jun 22. PMID: 26094546. Citato da 10. **IF:3.224**
46. Macchi B, Marino-Merlo F, Nocentini U, Pisani V, Cuzzocrea S, **Grelli S**, Mastino A. Role of inflammation and apoptosis in multiple sclerosis: Comparative analysis between the periphery and the central nervous system. **2015 J Neuroimmunol.** Oct 15;287:80-7. doi:10.1016/j.jneuroim.2015.08.016. PMID: 26439966. Citato da 45. **IF:3.125**
47. Vurchio C, Cordero FM, Faggi C, Macchi B, Frezza C, **Grelli S**, Brandi A. Approaches towards the synthesis of 7-halo-1,2-dihydroxyindolizidines (7-halolentiginosines) thwarting Grob fragmentation processes. **2015 TETRAHEDRON**, vol. 71, p. 5806-5813, ISSN: 0040-4020, doi:10.1016/j.tet.2015.03.108. Citato da 6. **IF:2.233**
48. Conigliaro P, Triggianese P, Perricone C, Chimenti MS, Di Muzio G, Ballanti E, Guarino MD, Kloeger B, Gigliucci G, Perricone R. Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment. **2014 Clin Exp Immunol.** Jul;177(1):234-43. doi:10.1111/cei.12335. PMID: 24666401. Citato da 55. **IF:3.278**
49. Minutolo A, Conti B, **Grelli S**, Viscomi C, Labbadia G, Balsano A. Lymphocytes as liver damage mirror of HCV related adipogenesis deregulation. **2014 PLoS One.** March 21;9(3): e62343. doi:10.1371/journal.pone.0092343. e Collection. PMID: 24658135. Citato da 7. **IF:3.534**
50. Cordero FM, Bonanno P, Bhushan BK, Cardona F, Brandi A, Macchi B, Minutolo A, **Grelli S**, Mastino A. (-)-(1R,2R,7S,8aR)-1,2,7-Trihydroxyindolizidine[(-)-7S-Lentiginosine]. **2012 ChemPlusChem.** doi:10.1002/cplu.201100069. **IF:3.350**
51. Minutolo A\*, **Grelli S\***, Marino-Merlo F, Cordero FM, Brandi A, Macchi B, Mastino A. D(-) lentiginosine-induced apoptosis involves the intrinsic pathway and is p53-independent. **2012 Cell Death and Disease.** Jul 26;3:e358. doi:10.1038/cddis. **IF:5.333 \*Uguale contributo**
52. Kalimutho M, Minutolo A, **Grelli S**, Federici G, Bernardini S. Platinum-(IV)-derivative satraplatin induced G(2)/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells. **2011 Acta Pharmacol Sin.** Nov; 32 (11):1387-96. doi:10.1038/aps.2011.107. PMID: 21927014. Citato da 19. **IF:1.665**
53. [Kalimutho M](#), [Minutolo A](#), [Grelli S](#), [Formosa A](#), [Sancesario G](#), [Valentini A](#), [Federici G](#), [Bernardini S](#). Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance. **2011 Cancer Chemother Pharmacol.** Jul 26;3:e358. doi:10.1038/cddis. PMID: 20734047. Citato da 31. **IF:1.598**
54. Macchi B, Minutolo A, **Grelli S**, Cardona F, Cordero F, Mastino A, Brandi A. The novel proapoptotic activity of non-natural enantiomer of Lentiginosine. **2010 Glycobiology.** May 20: 500-506. doi:10.1093/glycob/cwp202. PMID: 20053629. Citato da 51. **IF:4.539**
55. Matteucci C, Minutolo A, Balestrieri E, Ascolani A, **Grelli S**, Macchi B, Mastino A. Effector caspase activation, in the absence of a conspicuous apoptosis induction, in mononuclear cells treated with azidothymidine. **2009 Pharmacol Res.** Feb 59: 125-33. doi:10.1016/j.phrs.2008.11.003. PMID: 19073261. Citato da 11. **IF:3.929**
56. Sciortino MT, Medici MA, Marino-Merlo F, Zaccaria D, Giuffrè-Cuculletto M, Venuti A, **Grelli S**, Bramanti P, Mastino A. Involvement of gD/HVEM interaction in NF- $\kappa$ B-dependent inhibition of apoptosis by HSV-1 gD. **2008 Biochem Pharmacol.** Dec 76: 1522-1532. doi:10.1016/j.bcp.2008.07.030. PMID: 18723002. Citato da 54. **IF:4.254**
57. Sciortino MT, Medici MA, Marino-Merlo F, Zaccaria D, Giuffrè-Cuculletto M, Venuti A, **Grelli S**, Mastino A. Involvement of HVEM receptor in activation of nuclear factor  $\kappa$ B by herpes simplex virus 1 glycoprotein D. **2008 Cell Microbiol.** Nov 10: 2297-2311. doi:10.1111/j.1462-5822.2008.01212.x. PMID: 18671825. Citato da 55. **IF:5.725**

58. Balestrieri E\*, **Grelli S\***, Matteucci C, Minutolo A, d'Ettorre G, Di Sora F, Montella F, Vullo V, Vella S, Favalli C, Macchi B, Mastino A. Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy. **2007 J Med Virol.** Feb 79: 111-117. doi:10.1002/jmv.20768. PMID: 17177302. Citato da 12. **IF:2.831 \*Uguale contributo**
59. Sciortino MT, Medici MA, Marino-Merlo F, Zaccaria D, Giuffre M, Venuti A, **Grelli S**, Mastino A. Signaling pathway used by HSV-1 to induce NF-kappaB activation: possible role of herpes virus entry receptor A. **2007 Ann N Y Acad Sci.** Jan 1096: 89-96. doi:10.1196/annals.1397.074. PMID: 17405920. Citato da 31. **IF:1.731**
60. Sciortino MT, Perri D, Medici MA, **Grelli S**, Serafino A, Borner C, Mastino A. Role of Bcl-2 expression for productive herpes simplex virus 2 replication. **2006 Virology.** Dec 356: 136-146. doi:10.1016/j.virol.2006.08.001. PMID: 16950491. Citato da 19. **IF:3.765**
61. **Grelli S**, Balestrieri E, Matteucci C, Minutolo A, d'Ettorre G, Lauria F, Montella F, Vullo V, Vella S, Favalli C, Mastino A, Macchi B. Apoptotic cell signaling in lymphocytes from HIV+ patients during successful therapy. **2006 Ann. N Y Acad. Sci.** Dec 1090: 130-137. doi:10.1196/annals.1378.014. PMID: 17384255. Citato da 6 **IF:1.731**
62. D'Agostini C, Pica F, Febbraio G, **Grelli S**, Chiavaroli C, Garaci E. Antitumor effect of OM-174 and cyclophosphamide on murine B-16 melanoma in different experimental conditions. **2005 Int. Immunopharmacol.** Jul 5: 1205-1212. doi:10.1016/j.intimp.2005.02.013. PMID: 15914325. Citato da 64. **IF:2.066**
63. Mango R, Biocca S, del Vecchio F, Clementi F, Sangiuolo F, Amati F, Filareto A, **Grelli S**, Spitalieri P, Filasi I, Favalli C, Lauro R, Mehta JL, Romeo F, Novelli G. In vivo and in vitro studies support that a new splicing isoform of ORL1 gene is protective against acute myocardial infarction. **2005 Circ. Res.** Jul 97: 152-158. doi:10.1161/01.RES.0000174563.62625.8e. PMID: 15976314. Citato da 127. **IF:9.251**
64. **Grelli S**, D'Ettorre G, Lauria F, Montella F, Di Traglia L, Lichtner M, Vullo V, Favalli C, Vella S, Macchi B, Mastino A. Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients. **2004 J Antimicrob Chemother.** Mar 53:494-500. doi:10.1093/jac/dkh105. PMID: 14963063. Citato da 14. **IF:4.038**
65. Tacconi S, Perri R, Balestrieri E, **Grelli S**, Bernardini S, Annichiarico R, Mastino A, Caltagirone C, Macchi B. Increase caspase activation in peripheral blood mononuclear cells of patients with Alzheimer's disease. **2004 Exp. Neurol.** 190: 254-262. doi:10.1016/j.expneurol.2004.07.009. PMID: 15473998. Citato da 52. **IF:3.982**
66. Mastino A, Favalli C, Camilli AR, Malerba C, **Grelli S**, Calugi A. Umbilical cord blood: the role of apoptosis in the control of CD34+ cell counts. **2003 Placenta.** Jan 24: 113-115. doi:10.1053/plac.2002.0873. PMID: 12495667. Citato da 12. **IF:3.238**
67. **Grelli S**, D'Ettorre G, Lauria F, Montella F, Di Traglia L, D'Agostini C, Lichtner M, Vullo V, Favalli C, Vella S, Macchi B, Mastino A. CD4+ lymphocyte increases in HIV patients during potent antiretroviral therapy are dependent on inhibition of CD8+ cell apoptosis. **2003 Ann N.Y. Acad. Sci.** Dec 1010: 560-564. doi:10.1196/annals.1299.104. PMID: 15033791. Citato da 6. **IF:1.731**
68. **Grelli S**, Di Traglia L, Matteucci C, Lichtner M, Vullo V, Di Sora F, Lauria F, Montella F, Favalli C, Vella S, Macchi B, Mastino A. Changes in apoptosis after interruption of potent antiretroviral therapy in patients with maximal HIV-RNA suppression. **2001 AIDS.** Jun 15: 1178-1181. Citato da 5. **IF:5.842**
69. Zhang J, Balestrieri E, **Grelli S**, Mattucci C, Pagnini V, D'Agostini C, Mastino A, Macchi B. Efficacy of 3'-azido 3'-deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blood mononuclear cells. **2001 Virus Res.** Oct 78: 67-78. doi:10.1016/s0168-1702(01)00285-4. PMID: 11520581. Citato da 25. **Q2, IF:2.810**
70. **Grelli S**, Campagna S, Lichtner M, Ricci G, Vella S, Vullo V, Montella F, Di Fabio S, Favalli C, Mastino A, Macchi B. Spontaneous and anti-Fas-induced apoptosis in lymphocytes from HIV-infected patients



undergoing highly active anti-retroviral therapy. **2000 AIDS**. May 14: 939-949. doi:10.1097/00002030-200005260-00005. **IF:5.842**

71. Giuliani C, Napolitano G, Mastino A, Di Vincenzo S, D'Agostini C, **Grelli S**, Bucci I, Singer DS, Kohn LD, Monaco F, Garaci E, Favalli C. Thymosin-alpha 1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. **2000 Eur. J. Immunol.** Mar 30: 778-786. doi:10.1002/1521-4141(200003)30:3<778::AID-IMMU778>3.0.CO;2-I. PMID: 10741392. Citato da 124. **IF:4.662**
72. Galante A, Pietroiusti A, Carta S, Franceschelli L, Piccolo P, Mastino A, Fontana C, **Grelli S**, Bergamaschi A, Magrini A, Favalli C. Infection with Helicobacter pylori and leukocyte response in patients with myocardial infarction. **2000 Eur. J. Clin. Microbiol. Infect. Dis.** Apr 19: 298-300. doi:10.1007/s100960050479. PMID: 10834820. Citato da 13. **IF:2.309**

Prof. Sandro Grelli

